5 unchanged sentences
On May 23, 2021 (the “Effective Date”), our Board of Directors (the “Board”) adopted the Global Equity Incentive Plan (the “2021 Plan”), which will continue in effect for ten years from the Effective Date.
−Removed: We intend to file one or more registration statements on Form S-8 under the Securities Act to register our shares issued or reserved for issuance under our equity incentive plans.
+Added: We have filed and intend to file registration statements on Form S-8 under the Securities Act to register our shares issued or reserved for issuance under our equity incentive plans.
The first such registration statement was filed on March 24, 2022 and automatically became effective upon filing with the SEC.
12 unchanged sentences
Equity compensation plans not approved by security holders
−Removed: As of March 1, 2024, there were approximately 45 holders of record of our common stock.
+Added: As of February 21, 2025, there were approximately 23 holders of record of our common stock.
The number of beneficial holders of our common stock does not reflect shareholders who hold shares in street name through brokerage accounts or other nominees.
5 unchanged sentences
333-260099) and our registration statement on Form S-1MEF (File No.
−Removed: 333-262512) (collectively, the “Registration Statements”) for our initial public offering were declared effective by the SEC.
+Added: 333-262512) (collectively, the “Registration Statements”) for our IPO were declared effective by the SEC.
Pursuant to such Registration Statements, we sold an aggregate of 3,200,000 shares of our common stock at a price of $5.00 per share for aggregate net cash proceeds of approximately $13.6 million, which amount is net of $1.12 million in underwriter’s discounts, commissions and expenses, and $1.3 million of other expenses incurred in connection with the offering.
12 unchanged sentences
As of December 31, 2024, we have sold 1,876,013 shares of our common stock and received $16.8 million in net proceeds under the ATM.
+Added: On February 5, 2025, in connection with the Registration Statement, we entered into an underwriting agreement (the "Underwriting Agreement”) with Lucid Capital Markets, LLC (the "Underwriter”).
+Added: Pursuant to the Underwriting Agreement, we agreed to sell to the Underwriter, in a firm commitment underwritten public offering, 2,700,000 shares (the "Firm Shares”) of our common stock, $0.00001 par value per share ("Common Stock”), at a price to the public of $5.00 per share, less underwriting discounts and commissions.
+Added: In addition, pursuant to the Underwriting Agreement, we granted the Underwriter an option, exercisable for 30 days, to purchase up to an additional 405,000 shares of Common Stock (the "Additional Shares”).
+Added: On February 5, 2025, the Underwriter exercised its option to purchase such Additional Shares in full.
+Added: The transaction closed on February 6, 2025.
+Added: The aggregate net proceeds are approximately $14.4 million after deducting underwriting discounts and commissions.
We intend to use the net proceeds from these offerings to fund the preclinical and clinical development of NXP800 and NXP900, to continue development and sponsored research related to our current product candidates or any future product candidate, hiring of additional personnel, capital expenditures, costs of operating as a public company and other general corporate purposes.
−Removed: There has been no material change in the expected use of the net proceeds from our initial public offering or private placement offering as described in our final prospectus filed with the SEC on February 8, 2022 and August 15, 2022, respectively, pursuant to Rule 424(b) under the Securities Act.
−Removed: We invested the funds received in an interest-bearing money market account.
+Added: There has been no material change in the expected use of the net proceeds from our IPO, public or private placement offerings as described in our final prospectus filed with the SEC on February 8, 2022 and February 6, 2025, respectively, pursuant to Rule 424(b) under the Securities Act.
+Added: We invest the funds received in an interest-bearing money market account.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.